Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer - Wikidata - wikimedia - TriplyDB

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

http://www.wikidata.org/entity/Q33730750

about

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report.Rexin-G, a targeted genetic medicine for cancer.Gammaretroviral vectors: biology, technology and application Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Library screening and receptor-directed targeting of gammaretroviral vectors.Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine.Overcoming drug resistance in pancreatic cancer.Current advances in retroviral gene therapy.Gene and cell therapy for pancreatic cancer.Nanovector-based therapies in advanced pancreatic cancer.Novel therapies for pancreatic cancer: setbacks and progress Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research.Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy.Pancreatic cancer gene therapy: from molecular targets to delivery systems.Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer.Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment.Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes.Efficacy and Safety of Pancreas-Targeted Hydrodynamic Gene Delivery in Rats.Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials.Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

P2860

Q26744830-A7224763-937A-4D36-9682-76104D572C14 Q26849375-2703508C-2C10-48AC-891A-97B6F2BEBF6A Q28077206-966C891C-9C3E-43EF-8AA8-26AB8E5E5517 Q30235405-F15D71CD-671B-447B-B6B5-69078193207D Q33748342-78906D9D-3EF7-4023-9361-020C695D362A Q34109646-8B9B5642-BCE0-4C8C-B1A8-9EF7BAB0F9C9 Q34223822-901640D3-F67F-45E3-8F93-6B130AF27646 Q34447986-3D1C94DE-DB6C-4216-90E4-937D10FD0B73 Q34517833-9B1573E3-EC34-4DD4-9B70-E52F3C447AF2 Q34657038-98A77B74-E384-4881-8245-81EC51BCFF18 Q35036615-B0F94AFF-4137-4D88-BFA1-5EACF0A25874 Q35237554-ED4F35F2-9085-4AED-9715-6732A68156E8 Q35541787-FFCFA504-2246-4289-B805-245D471BDD7C Q36097175-1C1EBA63-9AFE-4830-BDDB-A4E7423E7ED2 Q37107622-2E591116-AA52-4F61-A55D-E782C1F02A35 Q37981001-E025A415-CDF5-4B0A-B10D-2E80DE99AD7D Q38150365-1AD01078-2055-4416-80DB-672BB40C4B88 Q38161331-E5357186-023A-4083-B38A-0394F9503464 Q38221692-8A11F83C-CB5F-4A32-87BE-0B755D60F5EF Q38853466-741CCD37-F2B9-4C06-B626-E1FEFE9EE43F Q39350562-7F21514C-95A3-4126-877A-EFB2359331FE Q39359422-491E891E-ADF6-4EEB-9C60-F27B29AE504E Q46836744-435E8DF5-CDF0-444F-A89E-DCB311606702 Q55071436-47E0AE78-64C8-453B-AF90-01796E844B6A Q57618049-D4D57869-08B9-4BC5-A098-0D04391E49D6 Q58799265-EA5DE321-BEC3-4DE9-A12A-52DE2B0F7B1E

P2860

Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer

http://www.wikidata.org/entity/Q33730750

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@ast

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@en

type

label

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@ast

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@en

prefLabel

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@ast

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@en

P1433

Q33730750-B90226A7-9389-4048-B8CC-85FBB5A1B844

P1476

Q33730750-80D5B93E-0176-41C9-9A0B-76567DCC0B1B

P2093

Q33730750-4A8F7AC4-7245-43B6-A9C8-6790C2FBDCF9

Q33730750-5FFA58F9-15E1-4182-8F8E-16E8EACC40E8

Q33730750-8104D349-1259-484F-B980-6EA3193C6C9D

Q33730750-8345F236-DA61-41D2-8C0A-81F60E8176FE

Q33730750-9EE7F848-B397-4C1D-9285-23406F5B9D3C

Q33730750-A0CE3F3C-5E22-4597-AA82-4E1A65CE9E9F

Q33730750-DD14D030-DCD3-46AB-8027-3FE149639E6D

P2860

Q33730750-125D532E-12B2-44DE-B2E4-6CB9135896F9

Q33730750-145C612E-975D-4A8B-BABD-1C3E07B9517F

Q33730750-209493CC-8034-4460-8E12-BA01774A62B5

Q33730750-2AA0A209-F83D-4DF4-A61B-5F53B3BB275D

Q33730750-36E900BF-0EFF-42A3-9358-A28037FF314A

Q33730750-381006A8-6E2E-4352-AFDC-4CA0B270A6A8

Q33730750-3C16AC18-60D8-4D00-814F-3D8BBD67BCA3

Q33730750-407207C6-6F6E-455E-9002-E83A1FED70CE

Q33730750-47EA3FB7-8F42-45BB-A633-3E08CAC90C61

Q33730750-67166840-5FF3-4028-922F-5420A938B8F1

P304

Q33730750-F45BD8EB-479D-4B3E-ABF3-2A7C3F7B343F

P31

Q33730750-B2EBEB7F-190E-4A89-9A1E-B622AC4790C6

P356

Q33730750-A3D67539-E4ED-4124-8D23-2FEDDEFE23E8

P433

Q33730750-6A8332AC-3215-4A22-BD86-561053C698C5

P478

Q33730750-902D208F-8515-41C5-895A-B6878078DBB1

P577

Q33730750-02477A25-8518-44BB-9DBB-7F5CEBDB88C0

P5875

Q33730750-786E2325-F0B4-4F6C-B3CD-E65F925A8A49

P698

Q33730750-89345565-A8BE-4686-B042-7FE1FA2F8ECB

P932

Q33730750-4C231AFB-5C5D-459B-8A84-CFE41940ACDC

P356

P1433

Molecular Therapy

P1476

Advanced phase I/II studies of ...... t metastatic pancreatic cancer

@en

P2093

Dorris Quon

http://www.w3.org/2001/XMLSchema#string

Erlinda M Gordon

http://www.w3.org/2001/XMLSchema#string

Frederick L Hall

http://www.w3.org/2001/XMLSchema#string

Lita Fernandez

http://www.w3.org/2001/XMLSchema#string

Sant P Chawla

http://www.w3.org/2001/XMLSchema#string

Victoria S Chua

http://www.w3.org/2001/XMLSchema#string

William C Blackwelder

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor.

Pancreaticobiliary cancer: the future aspects of medical oncology.

Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Biological approaches to therapy of pancreatic cancer.

New directions in systemic therapy of pancreatic cancer.

Innovative treatments for pancreatic cancer.

P304

435-441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2009.228

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26891990

http://www.w3.org/2001/XMLSchema#string

P698

19826403

http://www.w3.org/2001/XMLSchema#string

P932

2839309

http://www.w3.org/2001/XMLSchema#string